At the end of 2022, FDA published a draft guidance on Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers. The draft guidance explains several aspects of the VMSR Program, including FDA’s approach to determining the eligibility of product codes for the program. Consistent with the goals outlined in the Medical Device User Fee Amendments of 2017 (MDUFA IV) Commitment Letter, the VMSR Program streamlines reporting of device malfunctions. The program began in 2018 when FDA issued an order granting an alternative reporting approach under 21 CFR 803.19. The ...
Blog Editors
Recent Updates
- AI Infrastructure, Ideology, and Exports: Inside the White House’s New AI Orders
- Texas Judge Strikes Down HIPAA’s Reproductive Health Amendment
- White House AI Action Plan Drops: Here’s What We Know
- AI Policy Alert: What to Know Before the White House Releases Its AI Action Plan
- Ninth Circuit Applies EKRA to Marketing Intermediaries in Lab Operator’s Allergy Testing Scheme